Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
The company's most advanced drug has taken a step toward FDA approval.
Wall Street is increasingly optimistic about this medical device company.
Income-focused investors should be able to count on these companies: a fast-food giant, a media empire, and a REIT in an unusual niche.
Not every company deserves to be in your 50-year portfolio, but owning these three could pay off handsomely.
Long-term catalysts could make these top stocks a savvy addition to portfolios.
Adding these top stocks to long-haul portfolios now could be profit-friendly.
These companies are making it easier for people to find caregivers for their aging parents and young children.
The enterprise search company's fiscal first-quarter results are sparking investor optimism.
What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.
HEXO could run into some legal troubles soon, and short sellers are eagerly awaiting a drop.
If you don't own these up-and-coming small companies in your investment portfolio yet, you could be missing out on a big opportunity for market-beating returns.
The company's second-quarter revenue is sparking optimism for future growth.
The insulin pump maker's second-quarter financial results are sparking optimism.
These stocks might not be household names, but they could still generate market-beating returns.
Here's what you should know if you want to buy and sell small-cap companies.
Investing in simple businesses like these could be key to market-beating returns.
Owning these big-cap stocks the next time the economy sours could be profit-friendly.
It could be a great time to add these income-friendly stocks to your dividend stock portfolio.
CannTrust growing pot in unlicensed rooms, Gilead Sciences’ deal with Galapagos to develop drugs, and more.